About Insulet Corp
- Industry: Health Care
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.omnipod.com
Frequently Asked Questions
What is the 52-week range for PODD?
The 52-week high is $354.88 and the 52-week low is $126.4.
What is the P/E ratio for PODD?
The Price to Earnings (P/E) ratio is 23.69.
What is the dividend yield for PODD?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 17.37%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 12.29%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 13.20.
Analyst Recommendation Trends
Wall Street analyst consensus for PODD over the last few months:
Latest PODD News
2 Safe-and-Steady Stocks to Consider Right Now and 1 Facing Challenges
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
Insulet to Announce Third Quarter 2026 Financial Results on November 4, 2026
ACTON, Mass., October 01, 2026--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the third quarter of 2026 on Wednesday, November 4, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time).
Insulet (NASDAQ:PODD) Offers Affordable Growth With Strong Fundamentals
Insulet (PODD) pairs strong growth and profitability with a reasonable valuation versus peers, making it a compelling affordable growth stock.
Insulet (PODD) Stock May Trade At A Discount To Fair Value
Insulet has seen its share price fall hard over the past year, which puts the focus squarely on whether the current market value still lines up with the cash the business is expected to generate. With the stock under pressure, the key issue now is how its cash flows compare with the price investors are paying today. Over the past 12 months, Insulet shares have declined 57.2%. This puts a lot of weight on whether the business can support the present valuation through its future cash...
2 Healthcare Stocks with Impressive Fundamentals and 1 Facing Challenges
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 38% over the past six months while the S&P 500 was up 16.9%.
Insulet (PODD) Reworked Its Debt, Is The Stock Still Cheap?
Insulet (PODD) recently reworked its financing by replacing $475 million of term loans with new debt at lower interest margins and expanding its revolving credit facility, a move that directly reshapes the balance sheet. Insulet’s refinancing lands after a tough stretch for the stock, with the share price down 52% year to date and the 1 year total shareholder return declining 58%. This points to fading momentum even before its recent index removal and conference appearances. Scan beyond...
Insulet Targets Type 2 Retention as Omnipod 6 and Global Growth Gain Momentum
Insulet (NASDAQ:PODD) Chief Operating Officer Eric Benjamin said the company remains focused on expanding adoption of automated insulin delivery, or AID, systems across large and underpenetrated diabetes markets, while addressing elevated early attrition among certain Type 2 diabetes customers. Spe
Insulet Corporation (PODD) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
Insulet Corporation (PODD) Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum September 24, 2026 12:30 PM EDTCompany...
How Is Insulet's Stock Performance Compared to Other Medical Devices Stocks?
Insulet has notably underperformed the Medical Devices industry over the past year, but analysts are cautiously optimistic about the stock’s prospects.
Insulet to Participate in Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum
ACTON, Mass., September 18, 2026--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum on Thursday, September 24, 2026, at 12:30 p.m. (Eastern Time).
BCSM Exits Insulet Corporation (PODD), Maintains Watchlist Status
Baron Capital, an investment management company, released its second-quarter 2026 investor letter for its “Baron SMID Cap ETF”. You can download the letter here. Baron SMID Cap ETF® (BCSM) gained 15.62% (NAV) in the second quarter, underperforming the Russell 2500 Growth Index’s 24.02% return. The trend towards “AI winners” continued, focusing on companies related to chips, […]
2 S&P 500 Stocks with Impressive Fundamentals and 1 We Turn Down
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.
Why Pay More For Stryker When BSX Stock Is On Sale?
A medical device giant now costs more than its faster-growing rivals, forcing investors to decide if its premium price tag is buying durable quality or just yesterday's story.
Beta Bionics’ insulin patch pump gets FDA nod
By bringing its first patch pump to market, Beta Bionics will be able to compete with industry leader Insulet.
Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Insulet Corporation (PODD) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 2:15 PM EDTCompany ParticipantsAshley McEvoy - CEO, President...
Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?
PODD's Omnipod 5 adoption, product expansion and raised international growth outlook support its growth prospects despite competitive and cost pressures.
Artisan Sold Insulet (PODD) Due to Competition Concerns
Artisan Partners, an investment management company, released its second-quarter 2026 investor letter for the “Artisan Mid Cap Fund”. The letter can be downloaded here. Global equities rebounded sharply in Q2 2026, recovering from March lows as resilient economic data, strong corporate earnings, and continued AI investment improved investor sentiment despite inflation concerns, delayed rate cuts, and […]
Why Is Insulet (PODD) Up 8.1% Since Last Earnings Report?
Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Baron SMID Cap ETF Q2 2026 Portfolio Activity
During the quarter, we initiated a position in Advanced Drainage Systems, the leading U.S. manufacturer of stormwater and onsite wastewater management products.
Unpacking Q2 Earnings: Insulet (NASDAQ:PODD) In The Context Of Other Patient Monitoring Stocks
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the patient monitoring industry, including Insulet (NASDAQ:PODD) and its peers.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-21 | McEvoy Ashley | +1,100 | $147.47 | $162,217 |
| 2026-08-01 | Davis Lisa Blair | -244 | $165.35 | $40,345 |
| 2026-07-01 | MAZELSKY JONATHAN JAY | +1,355 | - | - |
| 2026-06-30 | Huffines Robert Luther | +144 | $159.79 | $23,010 |
| 2026-06-30 | Huffines Robert Luther | +151 | $152.25 | $22,990 |
| 2026-06-03 | STONESIFER TIMOTHY C. | +2,790 | $143.51 | $400,393 |
| 2026-06-03 | BORIO LUCIANA | -418 | $143.27 | $59,887 |
| 2026-06-03 | WEATHERMAN ELIZABETH H | +3,450 | $144.2 | $497,490 |
| 2026-05-20 | WEATHERMAN ELIZABETH H | +1,660 | - | - |
| 2026-05-20 | STONESIFER TIMOTHY C. | +1,660 | - | - |
| 2026-05-20 | Scannell Timothy J | +1,660 | - | - |
| 2026-05-20 | MINOGUE MICHAEL R | +1,660 | - | - |
| 2026-05-20 | Huffines Robert Luther | +1,660 | - | - |
| 2026-05-20 | Hopfield Jessica | +1,660 | - | - |
| 2026-05-20 | Frederick Wayne A.I. | +1,660 | - | - |
| 2026-05-20 | BORIO LUCIANA | +1,660 | - | - |
| 2026-05-13 | McEvoy Ashley | -1,411 | $148.84 | $210,013 |
| 2026-04-01 | Panos Michael | +7,255 | - | - |
| 2026-04-01 | Panos Michael | +2,777 | - | - |
| 2026-03-31 | Huffines Robert Luther | +111 | $209.84 | $23,292 |
| 2026-02-27 | Singh Prem | -62 | $246.61 | $15,290 |
| 2026-02-27 | Singh Prem | -207 | $246.61 | $51,048 |
| 2026-02-27 | Cousin Laetitia | -53 | $246.61 | $13,070 |
| 2026-02-27 | Cousin Laetitia | -200 | $246.61 | $49,322 |
| 2026-02-27 | Budden Lauren | -99 | $246.61 | $24,414 |
| 2026-02-27 | Budden Lauren | -119 | $246.61 | $29,347 |
| 2026-02-27 | Kapples John W. | -194 | $246.61 | $47,842 |
| 2026-02-27 | Kapples John W. | -411 | $246.61 | $101,357 |
| 2026-02-27 | Benjamin Eric | -268 | $246.61 | $66,091 |
| 2026-02-27 | Benjamin Eric | -644 | $246.61 | $158,817 |
| 2026-02-25 | Kapples John W. | -263 | $248.12 | $65,256 |
| 2026-02-25 | Singh Prem | -138 | $248.12 | $34,241 |
| 2026-02-25 | Cousin Laetitia | -111 | $248.12 | $27,541 |
| 2026-02-25 | Budden Lauren | -55 | $248.12 | $13,647 |
| 2026-02-25 | Benjamin Eric | -395 | $248.12 | $98,007 |
| 2026-02-25 | MINOGUE MICHAEL R | +2,030 | $246.23 | $499,847 |
| 2026-02-24 | Kapples John W. | +4,907 | - | - |
| 2026-02-24 | Kapples John W. | +1,885 | - | - |
| 2026-02-24 | Pease Flavia | +9,946 | - | - |
| 2026-02-24 | Pease Flavia | +3,822 | - | - |
| 2026-02-24 | McEvoy Ashley | +26,143 | - | - |
| 2026-02-24 | McEvoy Ashley | +10,046 | - | - |
| 2026-02-24 | Singh Prem | +5,570 | - | - |
| 2026-02-24 | Singh Prem | +2,140 | - | - |
| 2026-02-24 | Cousin Laetitia | +2,718 | - | - |
| 2026-02-24 | Cousin Laetitia | +1,044 | - | - |
| 2026-02-24 | Budden Lauren | +1,591 | - | - |
| 2026-02-24 | Budden Lauren | +611 | - | - |
| 2026-02-24 | Benjamin Eric | +9,946 | - | - |
| 2026-02-24 | Benjamin Eric | +3,822 | - | - |
| 2026-02-24 | Davis Lisa Blair | +5,570 | - | - |
| 2026-02-24 | Davis Lisa Blair | +2,140 | - | - |
| 2026-02-20 | McEvoy Ashley | +4,300 | $239.35 | $1,029,205 |
| 2026-02-12 | Singh Prem | -861 | $240.82 | $207,346 |
| 2026-02-12 | Singh Prem | +2,532 | - | - |
| 2026-02-12 | Kapples John W. | -1,929 | $240.82 | $464,542 |
| 2026-02-12 | Kapples John W. | +5,246 | - | - |
| 2026-02-12 | Cousin Laetitia | -564 | $240.82 | $135,822 |
| 2026-02-12 | Cousin Laetitia | +1,808 | - | - |
| 2026-02-12 | Budden Lauren | -622 | $240.82 | $149,790 |
| 2026-02-12 | Budden Lauren | +1,808 | - | - |
| 2026-02-12 | Benjamin Eric | -2,887 | $240.82 | $695,247 |
| 2026-02-12 | Benjamin Eric | +7,236 | - | - |
| 2026-01-02 | Cousin Laetitia | -140 | $282.92 | $39,609 |
| 2025-12-31 | Huffines Robert Luther | +51 | $284.24 | $14,496 |
| 2025-12-15 | Frederick Wayne A.I. | -1,851 | $293.09 | $542,510 |
| 2025-12-05 | STONESIFER TIMOTHY C. | +962 | $311.73 | $299,884 |
| 2025-10-31 | Huffines Robert Luther | +477 | - | - |